Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + temozolomide in recurrent extensive-stage small cell lung cancer (Phase II)
ChiCTR2500104835Phase 2Not yet recruiting
- Sponsor
- Zigong Fourth People's Hospital
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and temozolomide in small cell lung cancer (SCLC), sponsored by Zigong Fourth People's Hospital. Primary endpoints: Objective response rate (ORR) and Overall survival (OS). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
fluzoparibtemozolomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500104835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104835.